Table 1.
Characteristics of included studies in this meta-analysis.
| Study | Year | Country | Sample size | Study period | Age (year) Median (range) |
FIGO stage | Treatment | Cut-off value | Survival endpoints | Study center | Follow-up (month) Median (range) |
NOS score |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nie, D. | 2019 | China | 553 | 2009-2012 | 53 (22-83) | I-IV | Surgery | 612 | OS, PFS | Single center | 46 (3-95) | 8 |
| Farolfi, A. | 2020 | Italy | 375 | 2007-2015 | 58 (31-83) | III-IV | Chemotherapy | 730 | OS, PFS | Multicenter | 1-125 | 9 |
| Liu, J. | 2020 | China | 108 | 2017-2019 | 57 | II-IV | Chemotherapy | 701 | PFS | Single center | 1-12 | 7 |
| Goenka, L. | 2022 | India | 49 | 2015-2019 | NA | III-IV | Chemotherapy | 639 | OS, PFS | Single center | 7 | 6 |
| Wang, J. | 2022 | China | 102 | 2017-2019 | 56 | III | Surgery+ chemotherapy |
872 | OS, PFS | Single center | 1-36 | 8 |
| Bizzarri, N. | 2023 | Italy | 359 | 2012-2019 | 54 (21-93) | I-III | Surgery | 1000 | OS, PFS | Single center | 31 | 7 |
OS, overall survival; PFS, progression-free survival; FIGO, International Federation of Gynecology and Obstetrics; NOS, Newcastle-Ottawa Scale; NA, not available.